FSGS

1
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Apellis Pharmaceuticals
Apellis PharmaceuticalsAustralia - Hawthorn East
1 program
1
APL2Phase 2/31 trial
Active Trials
NCT07213960Not Yet Recruiting270Est. Dec 2029

Trial Timeline

Clinical trial activity over time

2025
2026
2027
2028
2029
Apellis PharmaceuticalsAPL2

Clinical Trials (1)

Total enrollment: 270 patients across 1 trials

A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis

Start: Dec 2025Est. completion: Dec 2029270 patients
Phase 2/3Not Yet Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space